Patents by Inventor Daniel R. Greve

Daniel R. Greve has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
    Patent number: 9586961
    Abstract: The invention relates to compounds of general formula (I) wherein R1, R2, R3, R4, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immuno-suppression would be desirable for example in organ transplantation.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: March 7, 2017
    Assignee: LEO PHARMA A/S
    Inventors: Simon Felbdæk Nielsen, Daniel R. Greve, Gunnar Grue-Sørensen, Carsten Ryttersgaard, Søren Christian Schou, Anette Graven Sams
  • NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF
    Publication number: 20130172325
    Abstract: The invention relates to compounds of general formula (I) wherein R1, R2, R3, R4, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immuno-suppression would be desirable for example in organ transplantation.
    Type: Application
    Filed: July 8, 2011
    Publication date: July 4, 2013
    Applicant: LEO PHARMA A/S
    Inventors: Simon Felbdæk Nielsen, Daniel R. Greve, Gunnar Grue-Sorensen, Carsten Ryttersgaard, Søren Christian Schou, Anette Graven Sams
  • Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives
    Patent number: 7612068
    Abstract: The present invention relates to compounds of formula I wherein the substituents are as defined below. The compounds of formula I are useful for the treatment of diseases such as schizophrenia, including both the positive and the negative symptoms of schizophrenia and other psychoses.
    Type: Grant
    Filed: April 27, 2004
    Date of Patent: November 3, 2009
    Assignee: H. Lundbeck A/S
    Inventors: Garrick P. Smith, Gitte K. Mikkelsen, Kim Andersen, Daniel R. Greve, Jorgen Eskildsen